Nuveen
CRSP icon

Nuveen’s CRISPR Therapeutics CRSP Stock Holding History

Nuveen’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
203,089
+12,323
+6% +$650K ﹤0.01% 1626
2026
Q1 		$9.07M Buy
190,766
+7,382
+4% +$389K ﹤0.01% 1614
2025
Q4 		$9.62M Buy
183,384
+543
+0.3% +$32.5K ﹤0.01% 1578
2025
Q3 		$11.8M Sell
182,841
-2,012
-1% -$116K ﹤0.01% 1461
2025
Q2 		$8.99M Buy
+184,853
New +$7.15M ﹤0.01% 1578
2024
Q4 		– Sell
-22,183
Closed -$1.04M – 3328
2024
Q3 		$1.04M Sell
22,183
-497
-2% -$25.2K ﹤0.01% 2741
2024
Q2 		$1.22M Sell
22,680
-6,823
-23% -$395K ﹤0.01% 2627
2024
Q1 		$2.01M Buy
29,503
+2,541
+9% +$182K ﹤0.01% 2402
2023
Q4 		$1.69M Sell
26,962
-11,847
-31% -$655K ﹤0.01% 2489
2023
Q3 		$1.76M Buy
38,809
+920
+2% +$47.5K ﹤0.01% 2348
2023
Q2 		$2.13M Buy
+37,889
New +$2.15M ﹤0.01% 2317
2021
Q4 		– Sell
-138,987
Closed -$15.6M – 3339
2021
Q3 		$15.6M Buy
138,987
+6,596
+5% +$828K ﹤0.01% 1448
2021
Q2 		$21.4M Buy
132,391
+25,001
+23% +$3.04M 0.01% 1314
2021
Q1 		$13.1M Buy
107,390
+90
+0.1% +$13.6K ﹤0.01% 1625
2020
Q4 		$16.4M Buy
107,300
+42,370
+65% +$5.01M 0.01% 1373
2020
Q3 		$5.43M Buy
64,930
+45,231
+230% +$4.01M ﹤0.01% 1868
2020
Q2 		$1.45M Sell
19,699
-4,173
-17% -$244K ﹤0.01% 2464
2020
Q1 		$1.01M Sell
23,872
-7,949
-25% -$410K ﹤0.01% 2510
2019
Q4 		$1.94M Sell
31,821
-495
-2% -$27K ﹤0.01% 2428
2019
Q3 		$1.32M Buy
+32,316
New +$1.54M ﹤0.01% 2572

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's CRSP Position: Q2 2026 in Review

Nuveen increased its CRISPR Therapeutics (CRSP) stake by 6.5% in Q2 2026, buying an estimated $650K and bringing the position to 203,089 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

Nuveen first reported a position in CRSP in Q3 2019 and has held it in 20 quarters since. The position peaked at $21.4M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Nuveen held 203,089 shares of CRISPR Therapeutics worth $11.1M as of Q2 2026.
  • Nuveen bought 12,323 CRISPR Therapeutics shares in Q2 2026, an estimated $650K.
  • CRISPR Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1626 holding.
  • Nuveen first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 20 quarters since.
  • Nuveen's CRISPR Therapeutics position peaked at $21.4M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.